SCM
EDIT icon

SCS Capital Management’s Editas Medicine EDIT Stock Holding History

SCS Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113K Hold
35,000
– – ﹤0.01% 476
2026
Q1 		$86.5K Hold
35,000
– – ﹤0.01% 462
2025
Q4 		$71.8K Hold
35,000
– – ﹤0.01% 489
2025
Q3 		$121K Hold
35,000
– – ﹤0.01% 501
2025
Q2 		$77K Hold
35,000
– – ﹤0.01% 543
2025
Q1 		$40.6K Buy
+35,000
New +$51.5K ﹤0.01% 510

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCS Capital Management's EDIT Position: Q2 2026 in Review

SCS Capital Management held its Editas Medicine (EDIT) position steady in Q2 2026 at 35,000 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #476.

SCS Capital Management first reported a position in EDIT in Q1 2025 and has held it in 6 quarters since. The position peaked at $121K in Q3 2025. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • SCS Capital Management held 35,000 shares of Editas Medicine worth $113K as of Q2 2026.
  • SCS Capital Management left its Editas Medicine share count unchanged in Q2 2026.
  • Editas Medicine made up ﹤0.01% of SCS Capital Management's portfolio in Q2 2026, its #476 holding.
  • SCS Capital Management first reported a position in Editas Medicine in Q1 2025 and has held it in 6 quarters since.
  • SCS Capital Management's Editas Medicine position peaked at $121K in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.